Search

We had a great time kicking off PHAVES for 2021 this week — thanks to everyone who attended! We had an awesome casual chat with phage researchers around the world, heard about what people are working on, what they're proud of from 2020, and

Fantastic turnout for the first Africa Phage Forum webinar this week — thanks to the ~70 attendees who were there, and thanks to Dr. Paul Turner who gave a thought-provoking talk and extensive Q&A! Sign up for future Africa Phage Forum eve

Paris phage biotech company Eligo Bioscience announced a new agreement worth up to $224M with GlaxoSmithKline, which is aimed at advancing Eligobiotics® for acne treatment/prevention. Eligo employs CRISPR-based phage therapeutics for microb

Anushila Chatterjee (University of Colorado School of Medicine) and colleagues published a new paper in PLOS Genetics showing phage infection and sub-lethal antibiotic exposure mediate Enterococcus faecalis type VII secretion system depende

Fernando Gordillo Altamirano (Monash University, Australia) and colleagues published a new paper in Nature Microbiology showing that phage-resistant Acinetobacter baumannii are resensitized to antimicrobials. They found that phage-resistant

Duhita Sant (Monash University, Australia) and colleagues published a new paper in Nature Ecology & Evolution showing that host diversity slows phage adaptation by selecting generalists over specialists. These findings support the evolution

Megha Shah (University of Toronto) and colleagues published a new paper in Molecular Cell showing how a phage-encoded anti-activator inhibits quorum sensing in Pseudomonas aeruginosa.

The NCTC in England has freshly re-characterized 100 phages originally collected for bacterial typing in the 1950s-1990s. If you want your phages to last as long as these, this is a great place to deposit! The National Collection of Type Cu

The University of Georgia is hiring an assistant professor of Microbial Systems Biology.

In celebration of our 100th issue of Capsid & Tail, we launched a survey called State of Phage 2020! We created this survey to help us all better understand the phage research community globally, including what kind of phages people are col

This issue was sponsored by Kisaco Research for Phage Futures 2021.

Vysnova (Silver Spring, MD) is seeking a highly qualified and motivated Research Technician III - Bacteriophage Therapeutics to work on a WRAIR contract.

The fifth iVoM event will be Thursday, January 21, 4pm GMT, and the theme will be "Agro-food, veterinary and environmental biotechnology applications". It will feature talks by: Sam R. Nugen - Department of Food Science and Technology, Co

The Africa Phage Forum is hosting its next phage webinar in its series, Feb 15 at 4pm GMT / 11am Eastern with special guest Dr. Evelien Adriaenssens, who will give a talk entitled Basics of phage genome annotation and classification - how t

PHAVES #11 will be a casual mixer to kick off the new year! We'll get together on Zoom January 12 at 11:00 AM Eastern. We'll start off with a bit of an "open mic" / "show and tell", where attendees will have the option to share something th

The Africa Phage Forum is hosting a new phage webinar series, starting Jan. 14 at 11AM EST (4PM GMT) with special guest Dr. Paul Turner. Dr. Turner will give a talk entitled 'From the environment to bedside: understanding the basics of phag

The fifth iVoM event will be Thursday, January 21, 4pm GMT, and the theme will be "Agro-food, veterinary and environmental biotechnology applications". It will feature talks by: Sam R. Nugen - Department of Food Science and Technology, Co

The TAILOR team at Baylor College of Medicine now has a YouTube channel! Check out their recent one, a recorded talk on AMR and phage therapy by one of TAILOR's founders, Dr. Anthony Maresso, called Chasing Change: A moving pandemic, an ada

Phage Futures 2021 will have a young researcher showcase at their event this coming February! If you're a young researcher attending the conference ($149 for students — register here), don't forget to apply to present a poster virtually by

US biotech company Felix Biotechnology announced the initiation of its first clinical trial, CYPHY, a phase 1/2 single center trial that will test its first targeted phage therapy candidate, YPT-01, against chronic P. aeruginosa infections